RedHill Biopharma reported $702K in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Cara Therapeutics USD 0 0 Mar/2025
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 1.65M 10K Sep/2025
Cronos Group USD 28.74M 10.38M Dec/2025
RedHill Biopharma USD 702K 0 Jun/2024